

**Meitheal Pharmaceuticals Dactinomycin for Injection**

**Vermont New Drug Report**

|                                      |   |
|--------------------------------------|---|
| Product Name & Description           | Dactinomycin for Injection, USP 500mcg (0.5mg) 2mL SDV  |
| NDC                                  | 71288-0129-02   |
| WAC Price                            | \$1,400.00  |
| Effective Date                       | 4/20/2021   |
| Marketing Pricing Plan               | Meitheal markets generic dactinomycin as a therapeutic equivalent to the innovator (brand) drug. As such, Meitheal relies on the safety and efficacy findings of the FDA with respect to the innovator drug. Meitheal markets to group purchasing organizations (GPOs), Integrated Delivery Networks (IDNs), and hospital/alternate site (own use) customers based solely on price and availability and therefore does not engage in direct-to-consumer, direct-to-physician, or prescriber marketing. Meitheal does not market based on any aspects of the drug itself, nor does Meitheal aim to treat a certain number of patients. Rather, Meitheal evaluates the size of the total market for a particular drug and strives to achieve a certain market share for that product. |
| Patients per Month Description       | Because its dactinomycin product is a generic product and there are a number of alternative options available, Meitheal Pharmaceuticals does not track the number of patients that are prescribed dactinomycin. In addition, there are several indications where the use of dactinomycin is approved to treat a number of conditions. Meitheal reasonably estimates, based on information publicly available on cancer.org via the American Cancer Society, that there is potential for approximately 200,000 prescriptions of dactinomycin annually for treatment for a number of diseases.  |
| Breakthrough Therapy/Priority Review | N/A   |
| Date and price of acquisition        | N/A   |